Abstract: Disclosed herein is a method of treating dry eye with a KLK-13 antibody.

Abstract: Disclosed herein are novel analogs of cyclosporin, pharmaceutical compositions containing them, and methods for their use in the treatment of dry eye and other conditions.

Abstract: Disclosed herein are novel analogs of cyclosporin, pharmaceutical compositions containing them, and methods for their use in the treatment of dry eye and other conditions.

Abstract: Disclosed herein TPV1 is a method of treating ocular and systemic conditions by administering IL-10 and TPV134R polypeptides.

Abstract: Disclosed herein is a method of treating certain ocular and other diseases with an anti-IL-23p19 antibody.

Abstract: Disclosed herein is a method of treating ocular and systemic conditions by administering a TGF-?.

Abstract: Disclosed herein is a method of treating dry eye with a KLK-13 antibody.

Abstract: Disclosed herein is a method of treating dry eye with an IL-17 antibody.

Abstract: Methods of treating humans or animals having dysfunctional oral mucosal tissue are disclosed which include topically administering cyclosporine A, salts thereof and/or mixtures thereof in an oral cavity of the human or animal.

Abstract: The present invention provides a method for the treatment of inflammatory diseases and/or conditions, e.g. allergic conjunctivitis, uveitis or phacoanaphylactic endophthalmitis in an eye of a mammal, said method comprising administering to said mammal in need of treatment a therapeutically effective amount of a novel cyclosporin A derivative selected from the group consisting of compounds represented by the formula: wherein R1 is S-Alk-R wherein Alk is an alkylene linkage, preferably a methylene or poly methylene linkage, or a polyalkenylene linkage, e.g. a C3 to C6 alkenylenyl linkage and R is a hydrogen or a unsubstituted or substituted hydrocarbyl group.

Abstract: Methods of treating humans or animals having various conditions are disclosed which include administering a therapeutically effective amount of a cyclosporine component to the human or animal, thereby treating the condition. Among the conditions treated are systemic lupus eryhematosis, multiple sclerosis, maloplabia of the skin, oral frictional hyperkeratosis, oral manifestations of autoimmune blistering disease, oral lichen planus, aphthous ulcers, nasal polyps, rhinosporiodosis, sinusitis, iritis, carcinoid lung, laryngitis and atrophic gastritis.

Abstract: Disclosed herein are methods of treating ocular rosacea with cyclosporin A. Compositions and medicaments related thereto are also disclosed.

Abstract: Methods of treating humans or animals having rheumatoid arthritis are disclosed which include topically administering a therapeutically effective amount of a cyclosporine component to the human or animal, thereby treating the rheumatoid arthritis.

Abstract: Methods of treating humans or animals having various conditions are disclosed which include administering a cyclosporinee component. Among the conditions treated are dry mouth syndrome, verruciform xanthoma, achlorhydria, mucous cysts, oral submucous fibrosis, oral nevi, cancer of the oral mucosa, maloplakia of the genito-urinary tract, vulvovaginitis, helicobacter plylori infection, duodenal ulcers, peptic ulcers, conditions affecting the uterus and appendicitis.

Abstract: Methods of treating humans or animals having various conditions are disclosed which include administering a cyclosporine component. Among the conditions treated are dry mouth syndrome, verruciform xanthoma, achlorhydria, mucous cysts, oral submucous fibrosis, oral nevi, cancer of the oral mucosa, maloplakia of the genito-urinary tract, vulvovaginitis, helicobacter plylori infection, duodenal ulcers, peptic ulcers, conditions affecting the uterus and appendicitis.

Abstract: The invention relates to the use of brimonidine for treating ocular pain.

Abstract: The invention relates to the use of brimonidine for treating ocular pain.

Abstract: A method of accelerating corneal wound healing in the corneal anterior stroma and/or improving the quality of wound healing in a mammal comprises: (1) providing an ophthalmically compatible solution of platelet-derived growth factor; and (2) applying the solution to the cornea of a mammal at the time of or subsequent to occurrence of a corneal wound in a quantity sufficient to accelerate clinically detectable healing, the healing being accelerated through proliferation of epithelial cells and/or keratocytes of the cornea stimulated by application of the platelet-derived growth factor to the cornea. The platelet-derived growth factor can be selected from the group consisting of the AA isoform, the AB isoform, the BB isoform, and mixtures thereof. A preferable form of platelet-derived growth factor is a recombinantly-derived refolded B-chain homodimer of 119 amino acids, having the amino acid sequence of SEQ ID NO: 1. The concentration of platelet-derived growth factor in the solution can be from about 10 .mu.

Abstract: Irrigating solutions with thiol or disulfide containing compounds in physiologically acceptable salt solutions are described. The irrigating solutions are useful during surgery, particularly ophthalmic, neural, cardiovascular or otic surgery, to stabilize the affected tissue. Methods for their preparation and use are described.

Abstract: Methods for preventing and treating corneal haze resulting from exposure of the eye to laser irradiation are disclosed. The methods include administration of compositions of wound healing modulators to the eye. Compositions for use in preventing and treating the corneal haze are also disclosed.